Daré Bioscience’s (DARE) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a report released on Friday,Benzinga reports. HC Wainwright currently has a $12.00 price target on the biotechnology company’s stock.

Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.

Daré Bioscience Stock Performance

Shares of NASDAQ:DARE opened at $3.21 on Friday. The firm has a market cap of $27.43 million, a PE ratio of -5.44 and a beta of 1.34. The firm’s 50 day simple moving average is $3.56 and its 200-day simple moving average is $3.93. Daré Bioscience has a one year low of $3.05 and a one year high of $7.56.

Hedge Funds Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC raised its stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.